Clinical trials: Neovascular Macular Degeneration
Neovascular Age-Related Macular Degeneration
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
- Trial name
- NCT06223958
- Testing
- OTX-TKI (axitinib implant), Aflibercept
- Where
- 108 sites in United States, Argentina and 1 more
- Volunteers
- 344 people
- Sponsor
- Ocular Therapeutix, Inc.
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular…
- Trial name
- ELARA (NCT06491914)
- Testing
- Aflibercept 8 mg
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 1,126 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
- Trial name
- ONYX (NCT02713204)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 87 sites in United States
- Volunteers
- 365 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Degeneration
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration (AMD) who are receiving photodynamic therapy, or PDT…
- Trial name
- NCT00043680
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Eye Institute (NEI)
Dystrophy, Retinal
BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.
- Trial name
- NCT04690062
- Testing
- Brolucizumab-Dbll
- Where
- United Arab Emirates
- Volunteers
- 20 people
- Sponsor
- Benha University
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Neovascular Age-related Macular Degeneration, Macular Degeneration
Photodynamic Therapy for PDA in NV AMD
The purpose of this prospective observational study is to assess the potential clinical effects of adjunctive verteporfin photodynamic therapy (PDT) for persistent disease activity among patients with neovascular age-related…
- Trial name
- NCT02452840
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Neovascular Age-related Macular Degeneration
Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate changes in preferential hyperacuity perimeter (PHP) and fundus autofluorescence (FAF) in patients with neovascular age-related macular degeneration receiving combination of ranibizumab…
- Trial name
- NCT00967213
- Testing
- ranibizumab
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Novartis Korea Ltd.
Macular Degeneration
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational…
- Trial name
- nAMD (NCT07367282)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- 5 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Junyeop Lee
Neovascular Age-related Macular Degeneration
CLN-0046: Treatment of AMD Subjects With OTX-TKI
To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).
- Trial name
- NCT03630315
- Testing
- OTX-TKI, Anti-VEGF
- Where
- 6 sites in Australia
- Volunteers
- 29 people
- Sponsor
- Ocular Therapeutix, Inc.
Macular Degeneration
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese…
- Trial name
- PINE (NCT03335852)
- Testing
- Abicipar pegol
- Where
- 5 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Allergan
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
- Trial name
- NCT04537884
- Testing
- UBX1325
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Unity Biotechnology, Inc.
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Neovascular Age Related Macular Degeneration
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A study to use in home technology to reduce the burden of in office visits and injections.
- Trial name
- Liberty (NCT01863199)
- Testing
- Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Retinal Consultants of Arizona
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular…
- Conditions
- Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
- Trial name
- NCT02599064
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Macular Degeneration
Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.
Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 years old. Neovascular AMD, the most severe form and the most severe is characterized by the appearance, spread and growth of subretinal…
- Trial name
- NCT04988178
- Testing
- Data extraction from medical files
- Where
- Belgium
- Volunteers
- 34 people
- Sponsor
- Brugmann University Hospital
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration, Choroidal Neovascularization
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
- Trial name
- NCT01880788
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Sequenom, Inc.
Age-related Macular Degeneration
Dose Ranging Study of Carbidopa-levodopa
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03023059
- Testing
- Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Neovascular Age-related Macular Degeneration
Safety and Efficacy of AM712 in Patients with NAMD
The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with…
- Trial name
- NCT05345769
- Testing
- AM712(ASKG712)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- AffaMed Therapeutics Limited